Compassionate Use of Remdesivir for Patients with Severe Covid-19

2020 New England Journal of Medicine 2,887 citations

Abstract

In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.).

Keywords

Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BetacoronavirusCompassionate UseVirologyMedicineCoronavirus InfectionsCoronavirusInternal medicineOutbreakInfectious disease (medical specialty)

Affiliated Institutions

Related Publications

Publication Info

Year
2020
Type
article
Volume
382
Issue
24
Pages
2327-2336
Citations
2887
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

2887
OpenAlex

Cite This

Jonathan Grein, Norio Ohmagari, Daniel D. Shin et al. (2020). Compassionate Use of Remdesivir for Patients with Severe Covid-19. New England Journal of Medicine , 382 (24) , 2327-2336. https://doi.org/10.1056/nejmoa2007016

Identifiers

DOI
10.1056/nejmoa2007016